Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
LL-37
Cathelicidin, Human Cathelicidin Antimicrobial Peptide
The only human cathelicidin antimicrobial peptide, LL-37 is a 37-amino-acid peptide naturally produced by immune cells, epithelial cells, and barrier tissues. It plays a critical role in innate immunity by directly killing bacteria, viruses, and fungi, while also modulating inflammatory responses. Increasingly studied for chronic infections, biofilm disruption, and immune regulation.
A synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in tissue repair and regeneration. Widely used in the biohacking community for injury recovery.
Disrupts microbial membranes through electrostatic interaction with negatively charged bacterial surfaces, creating pores that kill pathogens. Also modulates immune responses by recruiting immune cells, promoting wound healing, and disrupting bacterial biofilms. Acts as a bridge between innate and adaptive immunity.
Promotes cell migration, blood vessel formation, and reduces inflammation. Upregulates actin, a cell-building protein critical for healing and cell migration to injury sites.
- Immune system support
- Chronic infection management
- Biofilm disruption (Lyme, SIBO)
- Wound healing
- Upper respiratory infection support
- Muscle and tendon repair
- Wound healing
- Reducing inflammation
- Hair regrowth (emerging research)
- Cardiac tissue repair
- Injection site reactions (pain, redness)
- Potential autoimmune activation at high doses
- Limited human clinical data for therapeutic use
- Overexpression linked to psoriasis and rosacea in some contexts
- Limited human clinical data
- Potential tumor growth concerns (theoretical)
- Injection site reactions
- Headaches reported anecdotally
Not FDA-approved as a therapeutic. LL-37 is an endogenous human peptide being studied in clinical trials for wound healing and infection. Some compounding pharmacies have offered it, but it has no formal FDA category for compounding. Research is ongoing for topical wound applications.
On April 15, 2026, the FDA announced TB-500 will be removed from the Category 2 'significant safety risks' list effective April 22, 2026. Scheduled for PCAC review on July 23, 2026 to determine eligibility for the 503A bulk drug substances list. Compounding pharmacies should exercise caution until PCAC takes action.
PCAC: July 23, 2026
- Thymosin β4 promotes dermal healing
2007 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.